A5033609878- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Lung Cancer Research Studies
- Nutrition, Genetics, and Disease
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Circular RNAs in diseases
- RNA modifications and cancer
- Renal cell carcinoma treatment
- Head and Neck Cancer Studies
- Sarcoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Immunotherapy and Immune Responses
University of Palermo
2016-2025
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo
1994-2023
Temple University
2009-2023
University of Palermo
2001-2018
Clinica Luganese Moncucco
2000-2013
Weatherford College
2012-2013
Sbarro Health Research Organization
2009
Hôpital Tenon
2005
Sorbonne Université
2005
The University of Western Australia
2005
Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients colorectal cancer were invited to provide that data in a schematized format for inclusion collaborative database called RASCAL (The in-colorectal-cancer group). Our results from 2721 such have been presented previously first time any common cancer, showed conclusively different gene mutations impacts on outcome, even when occur at same site genome. To explore effect Ki-ras stages...
MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of different genes, including genes involved in cancer progression. A functional link between hypoxia, a key feature tumor microenvironment, and miRNA has been documented. We investigated whether how miR-20b can vascular endothelial growth factor (VEGF) MCF-7 breast cells under normoxic hypoxia-mimicking conditions (CoCl(2) exposure). Using immunoblotting, ELISA, quantitative real-time PCR, we demonstrated decreased...
// Francesco Passiglia 1, * , Giuseppe Bronte Viviana Bazan Clara Natoli 2 Sergio Rizzo 1 Antonio Galvano Angela Listì Cicero Christian Rolfo 3 Daniele Santini 4 Russo Section of Medical Oncology, Department Surgical, Oncological and Oral Sciences, University Palermo, Italy Medical, Biotechnological "G. D'Annunzio", Chieti, Phase I- Early Clinical Trials Unit, Oncology Multidisciplinary Center Antwerp (MOCA), Hospital, Edegem, Belgium Department, Campus Biomedico, Rome, These authors have...
Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable identifying patient who will benefit from immunotherapy remains an issue. We performed prospective study investigate if soluble forms immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, BTN2A1, could be candidate predict response blockade therapy. evaluated plasma levels in learning cohort metastatic clear cell...